Venlafaxine-moclobemide

From Psychiatrienet
Revision as of 15:02, 2 November 2015 by Anoek (talk | contribs)
Jump to: navigation, search
Venlafaxine
Type Antidepressant
Group SNRI
links
Medscape Venlafaxine
PubChem 5656
PubMed Venlafaxine
Kompas (Dutch) Venlafaxine
Wikipedia Venlafaxine
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from venlafaxine to moclobemide.[1] [2]

Nietinrijdenbord.png Stop venlafaxine
  • Before day 1: gradually reduce dosage of venlafaxine to a maximum of 75 mg/ day.
  • Day 1: reduce a dosage of 75 mg/day to 37,5 mg/day.
  • Day 8: stop administration of venlafaxine.
Eenrichtingbord.png Start moclobemide
  • Day 8-14: a wash-out period one week is necessary.
  • Day 15: start administration of moclobemide in a normal dosage of 300 mg/day.
Letopbord.png Cave
  • Occurrence of serotonin syndrome is reported when a wash-out period (of one week) is not considered.
Infobord.png More information
  • This switch is currently being reviewed.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.